Evidence map›Paper›PMID 38229877›Full record

ArticleBrain communications2024

Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.

Maxime Taquet, Zuzanna Skorniewska, Henrik Zetterberg, John R Geddes, Catherine J Mummery, James D Chalmers, Ling-Pei Ho, Alex Horsley, Michael Marks, Krisnah Poinasamy and 24 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 15 institutions in 3 countries.

Maxime TaquetDepartment of Psychiatry, University of Oxford, Oxford OX3 7JX, UK.
Zuzanna SkorniewskaDepartment of Psychiatry, University of Oxford, Oxford OX3 7JX, UK.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal 413 90, Sweden.ORCID https://orcid.org/0000-0003-3930-4354
John R GeddesDepartment of Psychiatry, University of Oxford, Oxford OX3 7JX, UK.
Catherine J MummeryDepartment of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.
James D ChalmersUniversity of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
Ling-Pei HoMRC Human Immunology Unit, University of Oxford, Oxford OX3 9DS, UK.
Alex HorsleyDivision of Infection, Immunity & Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK.
Michael MarksDepartment of Clinical Research, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.ORCID https://orcid.org/0000-0002-7585-4743
Krisnah PoinasamyAsthma and Lung UK, London E1 8AA, UK.
Betty RamanRadcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK.ORCID https://orcid.org/0000-0002-1239-9608
Olivia C LeavyDepartment of Population Health Sciences, University of Leicester, Leicester LE1 7RH, UK.
Matthew RichardsonThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester LE3 9QP, UK.
Omer ElneimaThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester LE3 9QP, UK.
Hamish J C McAuleyThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester LE3 9QP, UK.
Aarti ShikotraNIHR Leicester Biomedical Research Centre, University of Leicester, Leicester LE5 4PW, UK.
Amisha SingapuriThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester LE3 9QP, UK.
Marco SerenoThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester LE3 9QP, UK.
Ruth M SaundersThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester LE3 9QP, UK.
Victoria Claire HarrisThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester LE3 9QP, UK.
Linzy Houchen-WolloffCentre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester LE5 4PW, UK.
Parisa MansooriMQ: Transforming Mental Health, London EC1Y 0TH, UK.
Neil J GreeningThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester LE3 9QP, UK.
Ewen M HarrisonCentre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh EH16 4SS, UK.
Annemarie B DochertyCentre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh EH16 4SS, UK.
Nazir I LoneUsher Institute, University of Edinburgh, Edinburgh EH16 4SS, UK.
Jennifer QuintNational Heart and Lung Institute, Imperial College London, London SW3 6LY, UK.
William GreenhalfUniversity of Liverpool, Liverpool L69 3BX, UK.
Louise V WainDepartment of Population Health Sciences, University of Leicester, Leicester LE1 7RH, UK.
Christopher E BrightlingThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester LE3 9QP, UK.
Rachael E EvansThe Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester LE3 9QP, UK.
Paul J HarrisonDepartment of Psychiatry, University of Oxford, Oxford OX3 7JX, UK.ORCID https://orcid.org/0000-0002-6719-1126
Ivan KoychevDepartment of Psychiatry, University of Oxford, Oxford OX3 7JX, UK.ORCID https://orcid.org/0000-0001-6813-8493
PHOSP-COVID Study Collaborative Group
Oxford Health NHS Foundation Trust · GBUniversity of Oxford · GBUniversity of Leicester · GBUniversity of Liverpool · GBNHS Lothian · GBUniversity of Dundee · GBUniversity of Manchester · GBAsthma UK · GBImperial College London · GBUniversity of Edinburgh · GBMQ: Transforming Mental Health · GBRoyal London Hospital · GBUniversity of Wisconsin–Madison · USNational Hospital for Neurology and Neurosurgery · GBUniversity Hospitals of Leicester NHS Trust · GB

Funding

British Heart Foundation CH/F/21/90010Marie Curie MCCC-RP-14-A17178Medical Research Council G0600475Medical Research Council G1001128
6 · The paper itself

Abstract

A proportion of patients infected with severe acute respiratory syndrome coronavirus 2 experience a range of neuropsychiatric symptoms months after infection, including cognitive deficits, depression and anxiety. The mechanisms underpinning such symptoms remain elusive. Recent research has demonstrated that nervous system injury can occur during COVID-19. Whether ongoing neural injury in the months after COVID-19 accounts for the ongoing or emergent neuropsychiatric symptoms is unclear. Within a large prospective cohort study of adult survivors who were hospitalized for severe acute respiratory syndrome coronavirus 2 infection, we analysed plasma markers of nervous system injury and astrocytic activation, measured 6 months post-infection: neurofilament light, glial fibrillary acidic protein and total tau protein. We assessed whether these markers were associated with the severity of the acute COVID-19 illness and with post-acute neuropsychiatric symptoms (as measured by the Patient Health Questionnaire for depression, the General Anxiety Disorder assessment for anxiety, the Montreal Cognitive Assessment for objective cognitive deficit and the cognitive items of the Patient Symptom Questionnaire for subjective cognitive deficit) at 6 months and 1 year post-hospital discharge from COVID-19. No robust associations were found between markers of nervous system injury and severity of acute COVID-19 (except for an association of small effect size between duration of admission and neurofilament light) nor with post-acute neuropsychiatric symptoms. These results suggest that ongoing neuropsychiatric symptoms are not due to ongoing neural injury.

Indexed as

biomarkerslong COVIDneural injury

Identifiers

PMID38229877
PMCPMC10789589
OpenAlexW4390262532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.